Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Home/Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Oncology, Therapeutic, Diseases, Pharma & Healthcare

Publication ID:

GBI0717004

Publication Date:

July 01, 2017

Pages:

143

Publisher:

GBI Research

Region:

Asia Pacific

$4,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Summary

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.

The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients. A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Scope

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.
- How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
- What implications will the increased focus on targeted therapies have on the future of CRC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
- How could changes in risk factors such as population age, obesity and lifestyle influence the market?
Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 12
2.4.1 Etiology 12
2.4.2 Pathophysiology 13
2.4.3 Biomarkers/Targets of Interest 14
2.5 Diagnosis 15
2.5.1 Digital Rectal Examination 16
2.5.2 Fecal Occult Blood Test 16
2.5.3 Flexible Sigmoidoscopy 16
2.5.4 Colonoscopy 16
2.5.5 Virtual Colonoscopy 17
2.5.6 Double Contrast Barium Enema 17
2.6 Disease Stages 17
2.7 Prognosis 19
2.8 Treatment Guidelines and Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Chemotherapy 21
2.8.3 Targeted Therapies 22
2.8.4 Resistance to Pharmacological Therapies 23
2.8.5 Treatment Algorithm 23
3 Marketed Products 26
3.1 Overview 26
3.2 Chemotherapies 26
3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma 27
3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma 28
3.2.3 UFT (tegafur plus uracil) - Merck KGaA 29
3.3 Epidermal Growth Factor Receptor Targeted Therapies 29
3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA 30
3.3.2 Vectibix (panitumumab) - Amgen/Takeda 31
3.4 Anti-angiogenesis Therapies 33
3.4.1 Avastin (bevacizumab) - Roche 33
3.4.2 Cyramza (ramucirumab) - Eli Lilly 35
3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron 36
3.5 Kinase Inhibitors 37
3.5.1 Stivarga (regorafenib) - Bayer/Onyx 37
3.6 Comparative Efficacy and Safety of Marketed Products 38
4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 40
4.3 Pipeline by Molecular Target 43
4.4 Promising Pipeline Candidates 45
4.4.1 Keytruda (pembrolizumab) - Merck & Co. 45
4.4.2 Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) - Roche 47
4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma 49
4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma 50
4.4.5 Masitinib - AB Science 52
4.4.6 Fruquintinib (HMPL-013) - Hutchison MediPharma 54
4.4.7 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine 55
4.4.8 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing 56
4.4.9 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals 57
4.5 Comparative Efficacy and Safety of Pipeline Products 58
4.6 Product Competitiveness Framework 59
5 Clinical Trial Analysis 61
5.1 Failure Rate 61
5.1.1 Overall Failure Rate 61
5.1.2 Failure Rate by Phase and Molecule Type 62
5.1.3 Failure Rate by Phase and Molecular Target 63
5.2 Clinical Trial Size 64
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 64
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 65
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 66
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 67
5.3 Clinical Trial Duration 68
5.3.1 Trial Duration by Molecule Type and Stage of Development 68
5.3.2 Trial Duration by Molecular Target and Stage of Development 69
5.4 Summary of Clinical Trial Metrics 70
6 Multi-scenario Forecast 72
6.1 Overview 72
6.2 Asia-Pacific Market 72
6.3 India 74
6.3.1 Treatment Usage Patterns 74
6.3.2 Annual Cost of Therapy 75
6.3.3 Market Size 77
6.4 China 78
6.4.1 Treatment Usage Patterns 78
6.4.2 Annual Cost of Therapy 79
6.4.3 Market Size 80
6.5 Australia 81
6.5.1 Treatment Usage Patterns 81
6.5.2 Annual Cost of Therapy 81
6.5.3 Market Size 82
6.6 South Korea 83
6.6.1 Treatment Usage Patterns 83
6.6.2 Annual Cost of Therapy 84
6.6.3 Market Size 86
6.7 Japan 87
6.7.1 Treatment Usage Patterns 87
6.7.2 Annual Cost of Therapy 88
6.7.3 Market Size 89
7 Drivers and Barriers 90
7.1 Drivers 90
7.1.1 Increasing Elderly Population and Incidence of CRC 90
7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate 90
7.1.3 Increase in Mutation Testing to Drive Market Growth 90
7.1.4 Availability of Novel First-, Second- and third-Line Therapy Options in Pipeline 90
7.1.5 Diversified Healthcare Reform to Boost Market Growth 91
7.1.6 Diversified Health Insurance System to Help Nurture Growth 91
7.2 Barriers 92
7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth 92
7.2.2 High Prices of Therapeutics to Slow Down Market Growth 92
7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm 92
7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products 92
7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India 93
7.2.6 Drug Pricing Reforms 93
8 Deals and Strategic Consolidations 94
8.1 Licensing Deals 94
8.1.1 Deals by Region and Value 94
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 95
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 96
8.1.4 Key Licensing Deals 99
8.2 Co-development Deals 101
8.2.1 Deals by Region and Value 101
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 102
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 103
8.2.4 Key Co-development Deals 106
9 Appendix 108
9.1 All Pipeline Drugs by Stage of Development 108
9.1.1 Discovery 108
9.1.2 Preclinical 110
9.1.3 Investigational New Drug/Clinical Trial Authorization-Filed 115
9.1.4 Phase I 115
9.1.5 Phase II 119
9.1.6 Phase III 123
9.1.7 Pre-registration 123
9.2 Summary of Multi-scenario Market Forecasts to 2023 124
9.2.1 Asia-Pacific 124
9.2.2 India 124
9.2.3 China 124
9.2.4 Australia 125
9.2.5 South Korea 125
9.2.6 Japan 125
9.3 Bibliography 126
9.4 Abbreviations 136
9.5 Research Methodology 139
9.5.1 Secondary Research 140
9.5.2 Marketed Product Profiles 140
9.5.3 Late-Stage Pipeline Candidates 140
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 140
9.5.5 Product Competitiveness Framework 141
9.5.6 Pipeline Analysis 141
9.5.7 Forecasting Model 142
9.5.8 Deals Data Analysis 143
9.6 Contact Us 143
9.7 Disclaimer 143

List of Tables
1.1 List of Tables
Table 1: CRC Therapeutics Market, Symptoms of CRC 12
Table 2: CRC Therapeutics Market, Stage Definitions for CRC 18
Table 3: CRC Therapeutics Market, Prognosis for CRC 20
Table 4 CRC Therapeutics, Surgical Options for CRC 20
Table 5: CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2006-2017 101
Table 6: CRC Therapeutics Market, Global, Co-development Deals Value, 2006-2016 107
Table 7: CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017 108
Table 8: CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017 110
Table 9: CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2017 115
Table 10: CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017 115
Table 11: CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017 119
Table 12: CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017 123
Table 13: CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017 123
Table 14: CRC Therapeutics Market, APAC, Market Forecast, 2016-2023 124
Table 15: CRC Therapeutics Market, India, Market Forecast, 2016-2023 124
Table 16: CRC Therapeutics Market, China, Market Forecast, 2016-2023 124
Table 17: CRC Therapeutics Market, Australia, Market Forecast, 2016-2023 125
Table 18: CRC Therapeutics Market, South Korea, Market Forecast, 2016-2023 125
Table 19: CRC Therapeutics Market, Japan, Market Forecast, 2016-2023 125

List of Figures
1.2 List of Figures
Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013 11
Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC 24
Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 39
Figure 4: CRC Therapeutics Market, Global, Pipeline, 2017 42
Figure 5: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2017 44
Figure 6: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017 45
Figure 7: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2021-2023 47
Figure 8: CRC Therapeutics Market, APAC, Tecentriq plus Cotellic Forecast ($m), 2021-2023 48
Figure 9: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2021-2023 50
Figure 10: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021-2023 52
Figure 11: CRC Therapeutics Market, APAC, Masitinib Forecast ($m), 2019-2023 53
Figure 12: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018-2023 55
Figure 13: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2019-2023 56
Figure 14: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020-2023 57
Figure 15: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021-2023 58
Figure 16: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 58
Figure 17: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline First-Line Products, 2017 60
Figure 18: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016 62
Figure 19: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016 63
Figure 20: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016 64
Figure 21: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016 65
Figure 22: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016 66
Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016 67
Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016 68
Figure 25: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016 69
Figure 26: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016 70
Figure 27: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 71
Figure 28: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 71
Figure 29: CRC Therapeutics Market, APAC, Treatment Patterns (‘000), 2016-2023 73
Figure 30: CRC Therapeutics Market, APAC, Market Size ($bn), 2016-2023 74
Figure 31: CRC Therapeutics Market, India, Treatment Patterns (‘000), 2016-2023 75
Figure 32: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023 76
Figure 33: CRC Therapeutics Market, India, Market Size ($m), 2016-2023 77
Figure 34: CRC Therapeutics Market, China, Treatment Patterns (‘000), 2016-2023 78
Figure 35: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023 79
Figure 36: CRC Therapeutics Market, China, Market Size ($bn), 2016-2023 80
Figure 37: CRC Therapeutics Market, Australia, Treatment Patterns (‘000), 2016-2023 81
Figure 38: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023 82
Figure 39: CRC Therapeutics Market, Australia, Market Size ($m), 2016-2023 83
Figure 40: CRC Therapeutics Market, South Korea, Treatment Patterns (‘000), 2016-2023 84
Figure 41: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023 85
Figure 42: CRC Therapeutics Market, South Korea, Market Size ($m), 2016-2023 86
Figure 43: CRC Therapeutics Market, Japan, Treatment Patterns (‘000), 2016-2023 87
Figure 44: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023 88
Figure 45: CRC Therapeutics Market, Japan, Market Size ($bn), 2016-2023 89
Figure 46: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017 95
Figure 47: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 96
Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 97
Figure 49: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017 98
Figure 50: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017 99
Figure 51: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2017 102
Figure 52: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 103
Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 104
Figure 54: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016 105
Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016 106

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".